Natural Health Farm (NHEL) 10-Q 16 May 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Mar. 31, 2019	May 15, 2019
Document And Entity Information
Entity Registrant Name	NATURAL HEALTH FARM HOLDINGS INC
Entity Central Index Key	0001621697
Document Type	10-Q
Trading Symbol	NHEL
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity's Reporting Status Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		162,278,405
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

CONDENSED BALANCE SHEETS (Unaud

CONDENSED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Current Assets
Cash and cash equivalents	$ 1,255,178	$ 439,846
Account receivables - third parties	207,993	105,018
Account receivables - related parties	130,316	226,548
Other receivables and deposits	208,452	95,569
Inventories	512,792
Tax assets	8,112	5,463
Total Current Assets	2,322,843	872,444
Property, plant and equipment, net	777,486	159,146
Goodwill	1,118,843
Total Non-Current Assets	1,896,329	159,146
Total Assets	4,219,172	1,031,590
Current Liabilities
Accounts payable	197,040	69,805
Accrued expense	591,457	38,499
Payable to affiliate	653,346	311,337
Deferred revenue - third parties	38,361	48,694
Deferred revenue - related parties	44,174	57,341
Short term borrowings	539,326	40,000
Advances from directors	9,745	11,210
Total Current Liabilities	2,073,449	576,886
Deferred tax liabilities - Non-Current liabilities	6,912	6,817
Total Liabilities	2,080,361	583,703
Equity
Common Stock, $0.001 par value, 500,000,000 shares authorized, 162,177,000 shares and 161,555,000 shares issued and outstanding at March 31, 2019 and September 30, 2018, respectively	162,278	161,555
Additional Paid in Capital	2,562,782	857,783
Accumulated deficit	(1,097,418)	(1,071,993)
Foreign currency translation reserve	(2,285)	(16,758)
Merger reserve	517,300	517,300
Total equity attributable to owners of the Company	2,142,657	447,887
Non-controlling interests	(3,846)
Total Equity	2,138,811	447,887
Total Liabilities and Equity	$ 4,219,172	$ 1,031,590

CONDENSED BALANCE SHEETS (Una_2

CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2019	Sep. 30, 2018
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	500,000,000	500,000,000
Common stock, issued	162,177,000	161,555,000
Common stock, outstanding	162,177,000	161,555,000

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Revenues - related parties	$ 149,730	$ 213,659	$ 314,538	$ 215,658
Revenues - third parties	375,130	4,865	492,503	4,865
Total Revenues	524,860	218,524	807,041	220,523
Cost of Goods Sold	(217,365)	(120,494)	(339,942)	(121,100)
Gross Profit	307,495	98,030	467,099	99,423
Operating Expenses:
Consulting fees	(47,424)	(20,050)	(74,051)	(35,614)
Legal and filing fees	(32,870)	(20,810)	(45,865)	(23,715)
Other general and administrative	(366,654)	(70,582)	(410,687)	(70,582)
Total Operating and Administrative Expenses	(446,948)	(111,442)	(530,603)	(129,911)
Loss from Operations	(139,453)	(13,412)	(63,504)	(30,488)
Other income	1,109	606	3,492	606
Finance costs	(7,426)		(8,233)
Loss Before Provision For Income Tax	(145,770)	(12,806)	(68,245)	(29,882)
Provision for income tax
Net Loss	(145,770)	(12,806)	(68,245)	(29,882)
Other comprehensive income
Foreign currency translation differences	14,830	5,863	14,830	5,863
Total comprehensive expense for the period	(130,940)	(6,943)	(53,415)	(24,019)
Loss attributable to:
Owners of the Company	(102,950)	(12,806)	(25,425)	(29,882)
Non-controlling interests	(42,820)		(42,820)
Loss for the period	(145,770)	(12,806)	(68,245)	(29,882)
Total comprehensive expense attributable to:
Owners of the Company	(88,477)	(6,943)	(10,952)	(24,019)
Non-controlling interests	(42,463)		(42,463)
Total comprehensive expense for the period	$ (130,940)	$ (6,943)	$ (53,415)	$ (24,019)
Basic and Dilutive Net Loss Per Share (in dollars per share)	$ 0	$ 0	$ 0	$ 0
Weighted Average Number of Shares Outstanding - Basic and Diluted (in shares)	162,278,405	150,794,444	162,278,405	150,468,681

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash Flows from Operating Activities:
Net Loss	$ (68,245)	$ (29,882)
Adjustment to reconcile net loss to net cash (used in) provided by operating activities
Amortization of property, plant and equipment	67,879	4,094
Changes in operating assets and liabilities
Account receivables	68,093	(237,721)
Account payables	(164,113)	488,783
Inventories	(94,898)
Net Cash Flows (Used in) Provided by Operating Activities	(191,284)	225,274
Cash Flows from Investing Activities
Purchase of plant and equipment		(49,551)
Acquisition of subsidiaries, net of cash and cash equivalents acquired	(1,196,967)
Cash inflows from merger and acquisition, net		277,180
Net Cash Flows (Used in) Provided by Investing Activities	(1,196,967)	227,629
Cash Flows from Financing Activities
(Payment to) Advances from directors	(1,465)	11,313
Drawdowns of short term borrowings, net	499,326
Proceeds from issuance of shares	1,705,722
Net Cash Flows Provided by Financing Activities	2,203,583	11,313
Net Increase in Cash and Cash Equivalents	815,332	464,216
Cash and Cash Equivalents, Beginning of the Period	439,846
Cash and Cash Equivalents, End of the Period	1,255,178	464,216
Supplemental Disclosures of Cash Flow Information:
Cash paid for Income Taxes
Cash paid for Interest	$ (14,361)

NATURE OF OPERATIONS, BASIS OF

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND GOING CONCERN	6 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND GOING CONCERN	NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND GOING CONCERN Natural Health Farm Holdings Inc. (the “Company”, “We”, “Its”, and “NHEL”) was incorporated under the laws of the State of Nevada on July 10, 2014 (Inception date). The Company has developed web-based business and launched itself into the healthcare industry. The Company has plans to provide through its subsidiaries, retail nutritional supplements, organic foods, personal care, and other health care products. The company has positioned itself to be a fully integrated nutraceutical biotechnology company offering products and related services through healthcare practitioners and direct-to-consumers. The company now owns a research & development laboratory in Malaysia, franchisee management services company and an Australia manufacturing facility producing practitioner only naturopathic and homeopathic medicines. On November 30, 2016, the Company filed a certificate of amendment to its articles of incorporation with the Nevada Secretary of State to change its name from Amber Group Inc. to Natural Health Farm Holdings Inc. and effectuated a 30:1 forward stock split of its common stock and increased its authorized share capital to 500,000,000 (Five Hundred Million). This amendment was unanimously approved by the Company’s board of directors on November 29, 2016, and with the stockholders holding a majority of the Company’s voting power. On March 16, 2017, Financial Industry Regulatory Authority (FINRA) approved the corporate name change to Natural Health Farm Holdings Inc., approved the increase in the Company’s authorized shares of common stock to 500,000,000 shares, and approved 30:1 forward stock split effective March 17, 2017. The new trading symbol for our common stock is “NHEL”. On January 31, 2018, the company acquired the total outstanding share of NHF International Limited at at nominal value. Upon the completion of the acquisition, its subsidiaries, both Natural Tech R&D Sdn Bhd and NHF Management & Business Sdn Bhd become wholly subsidiaries of the Group. As this transaction is business combination under common control, as deliberated and determined by Directors of the Company, difference between purchase considerations and net tangible assets acquired is recorded in merger reserves which amounted to $517,300. Natural Tech R&D Sdn Bhd, a BioNexus Status Company in Malaysia, specializes in research and development, cultivation, extraction and commercialization of nutraceuticals based on medicinal fungi and NHF Management & Business Sdn Bhd, providing franchisee management services and consultation, such as point-of-sales system, resources, branding and marketing. On December 3, 2018, the Company agreed to purchase 51% of the issued and outstanding capital stock of Prema Life Pty Ltd and 60% of the issued and outstanding capital stock of GGLG Properties Pty Ltd, collectively in exchange for 304,500 shares of the Company’s common stock. On December 28, 2018, the parties mutually agreed to extend the closing date of the purchase transaction on January 1, 2019. The Company issued 304,500 shares of its common stock on December 3, 2018 in good faith for consummating the purchase. The corporate structure is depicted below: Basis of Presentation The accompanying interim condensed financial statements are unaudited, but in the opinion of management of the Company, contain all adjustments, which include normal recurring adjustments necessary to present fairly the financial position at March 31, 2019, and the results of operations for three months and six months ended March 31, 2019, and cash flows for the six months ended March 31, 2019 and 2018. The balance sheet as of September 30, 2017 is derived from the Company’s audited financial statements. Certain information and footnote disclosures normally included in financial statements that have been prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, although management of the Company believes that the disclosures contained in these interim condensed financial statements are adequate to make the information presented therein not misleading. For further information, refer to the financial statements and the notes thereto contained in the Company’s September 30, 2018 Annual Report filed with the Securities and Exchange Commission on Form 10-K on December 28, 2018. Going Concern The Company’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has generated small revenues and has sustained cumulative operating losses since July 10, 2014 (Inception Date) to date and allow it to continue as a going concern. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders and affiliates, the ability of the Company to obtain necessary financing to continue operations, and the attainment of profitable operations. The Company recorded a net loss of $68,245 from October 1, 2018 to March 31, 2019, with net cash out flows in operating activities of $191,284 and has an accumulated deficit of $1,097,418 as of March 31, 2019. These factors, among others, raise a substantial doubt regarding the Company’s ability to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations. The accompanying consolidated financial statements do not include any adjustments to reflect the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following summary of significant accounting policies of the Company is presented to assist in the understanding of the Company’s financial statements. The financial statements and notes are the representation of the Company’s management who is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America (“GAAP”) in all material respects and have been consistently applied in preparing the accompanying financial statements. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the valuation of accounts payable, accrued liabilities and payable to related party. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. The Company had a cash balance of $1,255,178 at March 31, 2019 and $439,846 at September 30, 2018, respectively. Property, Plant and Equipment Property, plant and equipment costs include direct costs incurred for purchase of fixed assets and payments made to independent suppliers. The Company accounts for property, plant and equipment costs in accordance with the FASB guidance for the costs of property, plant and equipment to be sold, leased, or otherwise marketed (“ASC Subtopic 985-20”). As for the computer software costs, they are capitalized once the technological feasibility of a product is established and such costs are determined to be recoverable. Technological feasibility of a product encompasses technical design documentation and integration documentation, or the completed and tested product design and working model. Computer software costs are capitalized once technological feasibility of a product is established and such costs are determined to be recoverable against future revenues. Technological feasibility is evaluated on a project-by-project basis. Amounts related to computer software development that are not capitalized are charged immediately to the appropriate expense account. Amounts that are considered ‘research and development’ that are not capitalized are immediately charged to engineering, research, and development expense. Capitalized costs for those products that are cancelled or abandoned are charged to product development expense in the period of cancellation. Commencing upon product release, capitalized computer software costs are amortized on the straight-line method over a thirty-six months period. The Company evaluates the future recoverability of capitalized computer software costs on an annual basis. Revenue Recognition and Concentrations We generate revenue from licensing and other software services from our web-based software to distributors and retailers of nutritional supplements in the healthcare industry. We recognize licensing fees and other software services as revenue over the period of the contract at the time that the computer software is delivered and accepted by the customer, the selling price is fixed, and collection is reasonably assured, provided no significant obligations remain. We consider authoritative guidance on multiple deliverables in determining whether each deliverable represents a separate unit of accounting. Deferred revenues represent billings or cash received in excess of revenue recognizable on service agreements that are not accounted for as revenues. Through our subsidiaries, Natural Tech R&D Sdn Bhd and Prema Life Pty Ltd, we generate revenue from distributing health supplements, naturopathic medicines and other health food products. Prema Life Pty Ltd also manufactured goods and packaging for contract clients. Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high quality banking institutions. The Company does not have the cash balances in excess of Federal Deposit Insurance Corporation limit at March 31, 2019 and September 30, 2018, respectively. Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “ Income Taxes” The Company follows the provisions of ASC 740-10, “ Accounting for Uncertain Income Tax Positions Earnings (Loss) Per Common Share The Company computes net earnings (loss) per share in accordance with ASC 260, “ Earnings per Share” Fair value of Financial Instruments and Fair Value Measurements ASC 820, “ Fair Value Measurements and Disclosures”, Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, accounts payable, accrued expenses and payable to an affiliate. Pursuant to ASC 820, “ Fair Value Measurements and Disclosures” Financial Instruments” The following table presents assets and liabilities that were measured and recognized at fair value as of March 31, 2019 on a recurring basis: Description Level 1 Level 2 Level 3 None $ - $ - $ - The following table presents assets and liabilities that were measured and recognized at fair value as of September 30, 2017 on a recurring basis: Description Level 1 Level 2 Level 3 None $ - $ - $ - Recent Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, “ Financial Instruments - Credit Losses In 2015, the FASB issued ASU No. 2015-17, “ Income Taxes” Balance Sheet Classification of Deferred Taxes

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	6 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 3 – PROPERTY, PLANT AND EQUIPMENT The amount capitalized include direct costs and incidental costs incurred in developing the software purchased from the third party. The following table presents details of our property, plant and equipment costs as of March 31, 2019 and September 30, 2018: Balance at September 30, 2018 Additions through acquisition of subsidiaries Amortization Balance at March 31, 2019 Property, plant and equipment, net $ 159,146 $ 686,219 $ (67,879 ) $ 777,486 Property, plant and equipment costs are being amortized on a straight-line basis over their estimated lives. The future amortization expense of property, plant and equipment costs as of March 31, 2019 are to be recorded in accordance with their estimated useful lives.

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	6 Months Ended
	Mar. 31, 2019
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable at March 31, 2019 and September 30, 2018 totaled $197,040 and $69,805, respectively. While the accrued expenses at March 31, 2019 and September 30, 2018 totaled $591,457 and 38,499, respectively.

PAYABLE TO AFFILIATES AND DRAWD

PAYABLE TO AFFILIATES AND DRAWDOWNS OF SHORT TERM BORROWINGS	6 Months Ended
	Mar. 31, 2019
Payable To Affiliates And Drawdowns Of Short Term Borrowings
PAYABLE TO AFFILIATES AND DRAWDOWNS OF SHORT TERM BORROWINGS	NOTE 5 – PAYABLE TO AFFILIATES AND DRAWDOWNS OF SHORT TERM BORROWINGS The Company has paid $1,465 previously advanced from a director for its working capital (see NOTE 6). The Company was granted short term borrowings from financial institutions for its working capital needs. The short term borrowings received is interest bearing as summarized below: Balance March 31, 2019 Balance September 30, (Unaudited) (Restated) Short term borrowings $ 539,326 $ 40,000 Total $ 539,326 $ 40,000 On February 15, 2019, the Company executed a convertible promissory note with Power Up Lending Group LTD (the “Power Up”), an unrelated-party, the sum of $138,888 together with any interest as set forth herein, on February 15, 2020 (the “Maturity Date”), and to pay interest on the unpaid principal balance hereof at the rate of eight percent (8%)(the “Interest Rate”) per annum from the date hereof (the “Issue Date”) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The total consideration received against the Note was $138,888, with the Note bearing $500 as a due diligence fee and $2,500 for legal expenses. On March 12, 2019, , the Company executed another convertible promissory note with Power Up Lending Group LTD (the “Power Up”), the sum of $128,000 together with any interest as set forth herein, on March 12, 2020 (the “Maturity Date”), and to pay interest on the unpaid principal balance hereof at the rate of eight percent (8%)(the “Interest Rate”) per annum from the date hereof (the “Issue Date”) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The total consideration received against the Note was $128,000, with the Note bearing $500 as a due diligence fee and $2,500 for legal expenses. On March 12, 2019, the Company executed a convertible promissory note with Labrys Fund, LP (the “Labrys”), an unrelated-party, a sum of up to $850,000, bearing an interest rate of 12%, per annum from the date hereof (the “Issue Date”) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise as provided herein. The maturity date of each tranche funded under this convertible promissory note shall be six (6) months from the funding date of the respective tranche (each a “Maturity Date”). The consideration to the Company for this Note is up to $765,000.00 (the “Consideration”) and carries a prorated original issue discount of up to $85,000.00 (the “OID”) Total consideration received of the first tranche was $126,000, including $3,000 for legal expenses. At the closing of the First Tranche, the outstanding principal amount under this Note shall be $140,000.00, consisting of the First Tranche plus the prorated portion of the OID. In connection with the funding of the First Tranche of the Note, the Company shall issue to Labrys, as a commitment fee, 92,105 shares of its common stock (the “First Returnable Shares”), as further provided in the Note, as well as to issue 15,000 shares (the “Commitment Shares”) to Labrys on the Closing Date, as a commitment fee. On March 19, 2019, the Company executed a convertible promissory note with Auctus Fund, LLC (the “Auctus”), an unrelated-party, a sum of $350,000, together with any interest as set forth herein, on December 19, 2019 (the “Maturity Date”), and to pay interest on the unpaid principal balance hereof at the rate of twelve percent (12%) (the “Interest Rate”) per annum from the date hereof (the “Issue Date”) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. ). The total consideration received against the Note was $350,000, with the Note bearing $35,000 as a due diligence fee and $2,750 for legal expenses. In connection with the funding of the Note, the Company shall issue to Auctus on the Closing Date, as a commitment fee, 35,000 shares of the Company’s common stock (the “Commitment Shares”), as well as 175,000 shares of its common stock (the “Returnable Shares”, as further provided in the Note). The Returnable Shares and Commitment Shares shall be deemed earned in full as of the Closing Date.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6 – RELATED PARTY TRANSACTIONS During the financial period under review, the Company paid an amount of $9,745 to the directors of the Company as of March 31, 2019, whilst received an advances of $11,210 from directors for its working capital needs as of September 30, 2018, respectively. Funds advanced to the Company by the director are non-interest bearing, unsecured and due on demand. The Company has received advances for its working capital needs from an affiliate in which the Company’s Chief Executive Officer holds the position of director in such entity (see NOTE 5). As for the sales to related parties, the amounts are disclosed on Condensed Statements Of Operations (PAGE 2).

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7 – COMMITMENTS AND CONTINGENCIES Litigation Costs and Contingencies From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business. Other than as set forth below, management is currently not aware of any such legal proceedings or claims that could have, individually or in the aggregate, a material adverse effect on our business, financial condition, or operating results. In the normal course of business, the Company incurs costs to hire and retain external legal counsel to advise it on regulatory, litigation and other matters. The Company expenses these costs as the related services are received. If a loss is considered probable and the amount can be reasonable estimated, the Company recognizes an expense for the estimated loss. Contingent liabilities that are probable to arise from the recent legal related to the company’s subsidiary Prema Life Pty Ltd, the details are disclosed on Part II, Item 1. Legal Proceedings (Page 18).

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	6 Months Ended
	Mar. 31, 2019
Equity [Abstract]
STOCKHOLDERS' DEFICIT	NOTE 8: STOCKHOLDERS’ DEFICIT The Company’s capitalization at March 31, 2018 was 500,000,000 authorized common shares with a par value of $0.001 per share. Common Stock On December 3, 2018, the Company agreed to purchase 51% of the issued and outstanding capital stock of Prema Life Pty Ltd and 60% of the issued and outstanding capital stock of GGLG Properties PTY Ltd, collectively in exchange for 304,500 shares of the Company’s common stock valued at $1,218,000 based on the fair value of the common stock on the closing date. On December 28, 2018, the parties mutually agreed to extend the closing of the purchase transaction on January 1, 2019. The Company issued 304,500 shares of its common stock on December 3, 2018 in good faith for consummating the purchase. The Company has recorded the fair value of the common stock issued as stock subscriptions receivable at December 31, 2018. On March 12, 2019, the Company executed a convertible promissory note with Labrys Fund, LP (the “Labrys”). In connection with the funding of the First Tranche of the Note, the Company shall issue to Labrys, as a commitment fee, 92,105 shares of its common stock (the “First Returnable Shares”), as further provided in the Note, as well as to issue 15,000 shares (the “Commitment Shares”) to Labrys on the Closing Date, as a commitment fee. On March 19, 2019, the Company executed a convertible promissory note with Auctus Fund, LLC (the “Auctus”). In connection with the funding of the Note, the Company shall issue to Auctus on the Closing Date, as a commitment fee, 35,000 shares of the Company’s common stock (the “Commitment Shares”), as well as 175,000 shares of its common stock (the “Returnable Shares”, as further provided in the Note). The Returnable Shares and Commitment Shares shall be deemed earned in full as of the Closing Date. On March 20, 2019, the company executed a convertible promissory note with EMA Financial, LLC (the “EMA”). In connection with the funding of the First Tranche of the Note, the Company shall issue to EMA, 15,000 shares of restricted common stock as a commitment fee the “Commitment Shares”), as well as 86,800 shares of restricted common stock (the “Returnable Shares”), as further provided in the Note). In the event the Company fails to redeem the tranche by its maturity date the Returnable Shares shall not be returned to the Company As a result of all common stock issuances, the Company had 162,278,405 shares and 161,555,000 shares of common stock issued and outstanding at March 31, 2019 and September 30, 2018, respectively.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 – SUBSEQUENT EVENTS Management has evaluated subsequent events through May 15, 2019, the date the financial statements were available to be issued, noting no items that would impact the accounting for events or transactions in the current period or require additional disclosure.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the valuation of accounts payable, accrued liabilities and payable to related party. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. The Company had a cash balance of $1,255,178 at March 31, 2019 and $439,846 at September 30, 2018, respectively.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment costs include direct costs incurred for purchase of fixed assets and payments made to independent suppliers. The Company accounts for property, plant and equipment costs in accordance with the FASB guidance for the costs of property, plant and equipment to be sold, leased, or otherwise marketed (“ASC Subtopic 985-20”). As for the computer software costs, they are capitalized once the technological feasibility of a product is established and such costs are determined to be recoverable. Technological feasibility of a product encompasses technical design documentation and integration documentation, or the completed and tested product design and working model. Computer software costs are capitalized once technological feasibility of a product is established and such costs are determined to be recoverable against future revenues. Technological feasibility is evaluated on a project-by-project basis. Amounts related to computer software development that are not capitalized are charged immediately to the appropriate expense account. Amounts that are considered ‘research and development’ that are not capitalized are immediately charged to engineering, research, and development expense. Capitalized costs for those products that are cancelled or abandoned are charged to product development expense in the period of cancellation. Commencing upon product release, capitalized computer software costs are amortized on the straight-line method over a thirty-six months period. The Company evaluates the future recoverability of capitalized computer software costs on an annual basis.
Revenue Recognition and Concentrations	Revenue Recognition and Concentrations We generate revenue from licensing and other software services from our web-based software to distributors and retailers of nutritional supplements in the healthcare industry. We recognize licensing fees and other software services as revenue over the period of the contract at the time that the computer software is delivered and accepted by the customer, the selling price is fixed, and collection is reasonably assured, provided no significant obligations remain. We consider authoritative guidance on multiple deliverables in determining whether each deliverable represents a separate unit of accounting. Deferred revenues represent billings or cash received in excess of revenue recognizable on service agreements that are not accounted for as revenues. Through our subsidiaries, Natural Tech R&D Sdn Bhd and Prema Life Pty Ltd, we generate revenue from distributing health supplements, naturopathic medicines and other health food products. Prema Life Pty Ltd also manufactured goods and packaging for contract clients.
Concentration of Risk	Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high quality banking institutions. The Company does not have the cash balances in excess of Federal Deposit Insurance Corporation limit at March 31, 2019 and September 30, 2018, respectively.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “ Income Taxes” The Company follows the provisions of ASC 740-10, “ Accounting for Uncertain Income Tax Positions
Earnings (Loss) Per Common Share	Earnings (Loss) Per Common Share The Company computes net earnings (loss) per share in accordance with ASC 260, “ Earnings per Share”
Fair value of Financial Instruments and Fair Value Measurements	Fair value of Financial Instruments and Fair Value Measurements ASC 820, “ Fair Value Measurements and Disclosures”, Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, accounts payable, accrued expenses and payable to an affiliate. Pursuant to ASC 820, “ Fair Value Measurements and Disclosures” Financial Instruments” The following table presents assets and liabilities that were measured and recognized at fair value as of March 31, 2019 on a recurring basis: Description Level 1 Level 2 Level 3 None $ - $ - $ - The following table presents assets and liabilities that were measured and recognized at fair value as of September 30, 2017 on a recurring basis: Description Level 1 Level 2 Level 3 None $ - $ - $ -
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, “ Financial Instruments - Credit Losses In 2015, the FASB issued ASU No. 2015-17, “ Income Taxes” Balance Sheet Classification of Deferred Taxes

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of assets and liabilities measured and recognized at fair value	The following table presents assets and liabilities that were measured and recognized at fair value as of March 31, 2019 on a recurring basis: Description Level 1 Level 2 Level 3 None $ - $ - $ - The following table presents assets and liabilities that were measured and recognized at fair value as of September 30, 2017 on a recurring basis: Description Level 1 Level 2 Level 3 None $ - $ - $ -

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	6 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment costs	The following table presents details of our property, plant and equipment costs as of March 31, 2019 and September 30, 2018: Balance at September 30, 2018 Additions through acquisition of subsidiaries Amortization Balance at March 31, 2019 Property, plant and equipment, net $ 159,146 $ 686,219 $ (67,879 ) $ 777,486

PAYABLE TO AFFILIATES AND DRA_2

PAYABLE TO AFFILIATES AND DRAWDOWNS OF SHORT TERM BORROWINGS (Tables)	6 Months Ended
	Mar. 31, 2019
Payable To Affiliates And Drawdowns Of Short Term Borrowings
Schedule of granted short term borrowings from financial institutions	The Company was granted short term borrowings from financial institutions for its working capital needs. The short term borrowings received is interest bearing as summarized below: Balance March 31, 2019 Balance September 30, (Unaudited) (Restated) Short term borrowings $ 539,326 $ 40,000 Total $ 539,326 $ 40,000

NATURE OF OPERATIONS, BASIS O_2

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative) - USD ($)	Dec. 03, 2018	Nov. 30, 2016	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Sep. 30, 2018
Description of forward stock split		30:1 forward stock split
Increased authorized share capital			500,000,000		500,000,000		500,000,000
Net loss			$ (145,770)	$ (12,806)	$ (68,245)	$ (29,882)
Accumulated deficit			(1,097,418)		(1,097,418)		$ (1,071,993)
Net cash used in operating activities					(191,284)	225,274
Number of shares issued (in shares)	304,500
Merger reserve			$ 517,300	$ 517,300	$ 517,300	$ 517,300	$ 517,300
Prema Life Pty Ltd [Member]
Percentage of ownership	51.00%
GGLG Properties Pty Ltd [Member]
Percentage of ownership	60.00%
Prema Life Pty Ltd And GGLG Properties Pty Ltd [Member]
Number of common shares conversion (in shares)	304,500

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Fair Value, Inputs, Level 1 [Member]
Assets and liabilities at fair value
Fair Value, Inputs, Level 2 [Member]
Assets and liabilities at fair value
Fair Value, Inputs, Level 3 [Member]
Assets and liabilities at fair value

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	6 Months Ended
	Mar. 31, 2019	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2017
Accounting Policies [Abstract]
Cash balance	$ 1,255,178	$ 439,846	$ 464,216
Useful life of computer software	36 months

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details)	6 Months Ended
	Mar. 31, 2019USD ($)
Property, Plant and Equipment [Abstract]
Balance at beginning	$ 159,146
Additions through acquisition of subsidiaries	686,219
Amortization	(67,879)
Balance at ending	$ 777,486

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Payables and Accruals [Abstract]
Accounts payable	$ 197,040	$ 69,805
Accrued expenses	$ 591,457	$ 38,499

PAYABLE TO AFFILIATES AND DRA_3

PAYABLE TO AFFILIATES AND DRAWDOWNS OF SHORT TERM BORROWINGS (Details) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Payable To Affiliates And Drawdowns Of Short Term Borrowings
Short term borrowings	$ 539,326	$ 40,000
Total	$ 539,326	$ 40,000

PAYABLE TO AFFILIATES AND DRA_4

PAYABLE TO AFFILIATES AND DRAWDOWNS OF SHORT TERM BORROWINGS (Details Narrative) - USD ($)	Mar. 19, 2019	Mar. 12, 2019	Feb. 15, 2019	Mar. 31, 2019	Mar. 31, 2018
(Payment to) Advances from directors				$ (1,465)	$ 11,313
Convertible Promissory Note [Member] | First Tranche [Member] | Labrys Fund, LP [Member] | Commitment Shares [Member]
Number of shares issued as commitment fee (in shares)		15,000
Convertible Promissory Note [Member] | First Tranche [Member] | Labrys Fund, LP [Member] | First Returnable Shares [Member]
Number of shares issued as commitment fee (in shares)		92,105
Convertible Promissory Note [Member] | First Tranche [Member] | Auctus Fund, LLC [Member] | Commitment Shares [Member]
Number of shares issued as commitment fee (in shares)	35,000
Convertible Promissory Note [Member] | First Tranche [Member] | Auctus Fund, LLC [Member] | First Returnable Shares [Member]
Number of shares issued as commitment fee (in shares)	175,000
Power Up Lending Group LTD [Member] | Convertible Promissory Note [Member]
Debt instrument		$ 128,000	$ 138,888
Debt instrument maturity date		Mar. 12, 2020	Feb. 15, 2020
Debt instrument interest rate		8.00%	8.00%
Proceeds from debt instrument		$ 128,000	$ 138,888
Due diligence fee		500	500
Legal expenses		2,500	$ 2,500
Labrys Fund, LP [Member] | Convertible Promissory Note [Member]
Debt instrument		$ 850,000
Debt instrument maturity terms		6 months
Debt instrument interest rate		12.00%
Proceeds from debt instrument		$ 765,000
Original issue discount		85,000
Labrys Fund, LP [Member] | Convertible Promissory Note [Member] | First Tranche [Member]
Proceeds from debt instrument		126,000
Legal expenses		3,000
Debt instrument principal amount		$ 140,000
Auctus Fund, LLC [Member] | Convertible Promissory Note [Member]
Debt instrument	$ 350,000
Debt instrument maturity date	Dec. 19, 2019
Debt instrument interest rate	12.00%
Proceeds from debt instrument	$ 350,000
Due diligence fee	35,000
Legal expenses	$ 2,750

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative)	Mar. 31, 2019USD ($)
Related Party Transactions [Abstract]
Due to director	$ 9,745
Advance from director	$ 11,210

STOCKHOLDERS' DEFICIT (Details

STOCKHOLDERS' DEFICIT (Details Narrative) - USD ($)	Mar. 20, 2019	Mar. 19, 2019	Mar. 12, 2019	Dec. 03, 2018	Mar. 31, 2019	Sep. 30, 2018
Common stock, authorized					500,000,000	500,000,000
Common stock, par value (in dollars per share)					$ 0.001	$ 0.001
Value of shares issued				$ 1,218,000
Number of shares issued (in shares)				304,500
Common stock, issued					162,177,000	161,555,000
Common stock, outstanding					162,177,000	161,555,000
Prema Life Pty Ltd [Member]
Ownership percentage				51.00%
GGLG Properties PTY Ltd [Member]
Ownership percentage				60.00%
Number of common shares conversion (in shares)				304,500
Convertible Promissory Note [Member] | EMA Financial, LLC [Member] | First Tranche [Member] | First Returnable Shares [Member] | Restricted Stock [Member]
Number of shares issued as commitment fee (in shares)	86,800
Convertible Promissory Note [Member] | EMA Financial, LLC [Member] | First Tranche [Member] | Commitment Shares [Member] | Restricted Stock [Member]
Number of shares issued as commitment fee (in shares)	15,000
Convertible Promissory Note [Member] | Auctus Fund, LLC [Member] | First Tranche [Member] | First Returnable Shares [Member]
Number of shares issued as commitment fee (in shares)		175,000
Convertible Promissory Note [Member] | Auctus Fund, LLC [Member] | First Tranche [Member] | Commitment Shares [Member]
Number of shares issued as commitment fee (in shares)		35,000
Convertible Promissory Note [Member] | Labrys Fund, LP [Member] | First Tranche [Member] | First Returnable Shares [Member]
Number of shares issued as commitment fee (in shares)			92,105
Convertible Promissory Note [Member] | Labrys Fund, LP [Member] | First Tranche [Member] | Commitment Shares [Member]
Number of shares issued as commitment fee (in shares)			15,000